Modulation of the Astrocyte-Neuron Lactate Shuttle System contributes to Neuroprotective action of Fibroblast Growth Factor 21

A viewpoint considering Alzheimer's disease (AD) as “type 3 diabetes” emphasizes the pivotal role of dysfunctional brain energy metabolism in AD. The hormone fibroblast growth factor 21 (FGF21) is a crucial regulator in energy metabolism; however, our understanding of the therapeutic potential and mechanisms underlying the effect of FGF21 on neurodegeneration of AD is far from complete. Methods: To further elucidate the effect of FGF21 on AD-related neurodegeneration, we used APP/PS1 transgenic mice to assess the effects of FGF21 on memory dysfunction, amyloid plaque pathology and pathological tau hyperphosphorylation. We also established an in vitro system to mimic astrocyte-neuron communication and an in vivo model of acute injury. Based on the in vivo and in vitro models, we analyzed the neuroprotective actions of FGF21 and pathways related to astrocyte-neuron communication and further focused on the astrocyte-neuron lactate shuttle system. Results: Here, we report that FGF21 can ameliorate Alzheimer-like neurodegeneration in APP/PS1 transgenic mice. We detected defects in the astrocyte-neuron lactate shuttle system in the in vivo and in vitro models of AD and identified FGF21 as a neuroprotective molecule that can rescue these deficits. Administration of FGF21 can alleviate memory dysfunction, amyloid plaque pathology and pathological tau hyperphosphorylation, and the function of FGF21 in neurodegeneration is mediated in part by monocarboxylate transporters (MCTs). In vivo evidence also suggests that FGF21 acts centrally in mice to exert its effects on neurodegeneration and energy metabolism via its regulation of MCTs. Conclusions: These results suggest that FGF21 alters metabolic parameters to mediate its neuroprotective functions. Modulation of the astrocyte-neuron lactate shuttle system can be one of the most efficient strategies for FGF21 in Alzheimer-like degeneration and contributes to improvements in brain metabolic defects and amyloid β-induced cytotoxicity. Our findings provide insights into the mechanisms underlying the effects of FGF21 on neurodegeneration and brain energy metabolism and suggest that FGF21 may have therapeutic value in the treatment of AD and other neurodegenerative diseases.

[1]  Peichang Wang,et al.  Role of monocarboxylate transporter 4 in Alzheimer disease. , 2019, Neurotoxicology.

[2]  A. Giménez-Cassina,et al.  Fibroblast growth Factor-21 promotes ketone body utilization in neurons through activation of AMP-dependent kinase , 2019, Molecular and Cellular Neuroscience.

[3]  Weiwei Zhang,et al.  Nitric oxide might be an inducing factor in cognitive impairment in Alzheimer's disease via downregulating the monocarboxylate transporter 1. , 2019, Nitric oxide : biology and chemistry.

[4]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[5]  H. Kiyonari,et al.  Hepatic posttranscriptional network comprised of CCR4–NOT deadenylase and FGF21 maintains systemic metabolic homeostasis , 2019, Proceedings of the National Academy of Sciences.

[6]  Xiangdong Gao,et al.  Evidence of metabolic memory-induced neurodegeneration and the therapeutic effects of glucagon-like peptide-1 receptor agonists via Forkhead box class O. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[7]  Xiangdong Gao,et al.  Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease , 2019, Redox biology.

[8]  L. Pellerin,et al.  Neuroprotective effect of rLosac on supplement‐deprived mouse cultured cortical neurons involves maintenance of monocarboxylate transporter MCT2 protein levels , 2018, Journal of neurochemistry.

[9]  Y. Li,et al.  Curcumin Ameliorates Memory Deficits by Enhancing Lactate Content and MCT2 Expression in APP/PS1 Transgenic Mouse Model of Alzheimer's Disease , 2018, Anatomical record.

[10]  Huan Liu,et al.  FGF21 Protects the Blood-Brain Barrier by Upregulating PPARγ via FGFR1/β-klotho after Traumatic Brain Injury. , 2018, Journal of neurotrauma.

[11]  S. Studenski,et al.  Metabolic Syndrome and Amyloid Accumulation in the Aging Brain. , 2018, Journal of Alzheimer's disease : JAD.

[12]  X. Tu,et al.  Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction , 2018, Theranostics.

[13]  L. Scorrano,et al.  Neuronal Mitochondrial Dysfunction Activates the Integrated Stress Response to Induce Fibroblast Growth Factor 21 , 2018, Cell reports.

[14]  Ping Li,et al.  Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway , 2018, Theranostics.

[15]  F. Villarroya,et al.  Autophagic control of cardiac steatosis through FGF21 in obesity-associated cardiomyopathy. , 2018, International journal of cardiology.

[16]  S. Kliewer,et al.  The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet and Alcohol. , 2018, Cell metabolism.

[17]  Xiangdong Gao,et al.  GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling , 2018, Neuropharmacology.

[18]  C. Rowe,et al.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions , 2018, Nature Reviews Neurology.

[19]  L. K. Bak,et al.  CrossTalk opposing view: lack of evidence supporting an astrocyte‐to‐neuron lactate shuttle coupling neuronal activity to glucose utilisation in the brain , 2018, The Journal of physiology.

[20]  B. Weber,et al.  CrossTalk proposal: an important astrocyte‐to‐neuron lactate shuttle couples neuronal activity to glucose utilisation in the brain , 2018, The Journal of physiology.

[21]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[22]  Ming Xu,et al.  Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy , 2018, Scientific Reports.

[23]  S. Kliewer,et al.  FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. , 2017, Cell metabolism.

[24]  H. Häring,et al.  Fibroblast Growth Factor 21—Metabolic Role in Mice and Men , 2017, Endocrine reviews.

[25]  J. Leszek,et al.  Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease. , 2017, Current topics in medicinal chemistry.

[26]  Matthew J. Potthoff,et al.  FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. , 2017, Cell metabolism.

[27]  Hunter S. Futch,et al.  Neuron–astrocyte signaling is preserved in the aging brain , 2017, Glia.

[28]  Bryan J. Neth,et al.  Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial , 2017, Journal of Alzheimer's disease : JAD.

[29]  S. Kliewer,et al.  FGF21 Is an Exocrine Pancreas Secretagogue. , 2017, Cell metabolism.

[30]  L. Schneider,et al.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial , 2016, The Lancet.

[31]  N. Chattipakorn,et al.  FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats , 2016, Hormones and Behavior.

[32]  N. Mellen,et al.  Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. , 2016, Clinical science.

[33]  Robert Bartha,et al.  AEROBIC GLYCOLYSIS IN THE FRONTAL CORTEX CORRELATES WITH MEMORY PERFORMANCE IN WILD-TYPE MICE BUT NOT THE APP/PS1 MOUSE MODEL OF CEREBRAL AMYLOIDOSIS , 2016, Alzheimer's & Dementia.

[34]  M. Gillum,et al.  FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver. , 2016, Cell metabolism.

[35]  Pierre J Magistretti,et al.  In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons. , 2016, Cell metabolism.

[36]  G. Ren,et al.  Fibroblast growth factor 21 protects mouse brain against d-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation , 2015, Pharmacology Biochemistry and Behavior.

[37]  Pierre J. Magistretti,et al.  A Cellular Perspective on Brain Energy Metabolism and Functional Imaging , 2015, Neuron.

[38]  J. Flier,et al.  Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. , 2015, Endocrinology.

[39]  E. Feldman,et al.  Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome , 2015, Experimental & Molecular Medicine.

[40]  Shanquan Sun,et al.  Changes in lactate content and monocarboxylate transporter 2 expression in Aβ25-35-treated rat model of Alzheimer’s disease , 2015, Neurological Sciences.

[41]  Andrei G. Vlassenko,et al.  Brain aerobic glycolysis functions and Alzheimer’s disease , 2015, Clinical and Translational Imaging.

[42]  S. Monte.  Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review , 2014, European Neuropsychopharmacology.

[43]  S. Kliewer,et al.  FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. , 2014, Cell metabolism.

[44]  A. Stefani,et al.  CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[45]  N. Belluardo,et al.  Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1 , 2014, SpringerPlus.

[46]  S. Kliewer,et al.  FGF21 regulates metabolism and circadian behavior by acting on the nervous system , 2013, Nature Medicine.

[47]  Nobuyuki Itoh,et al.  Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine , 2012, Nature Medicine.

[48]  Chaoming Wu,et al.  Dynamic change of serum FGF21 levels in response to glucose challenge in human. , 2012, The Journal of clinical endocrinology and metabolism.

[49]  A. Spada,et al.  Intercellular (Mis)communication in Neurodegenerative Disease , 2012, Neuron.

[50]  Pierre J Magistretti,et al.  Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. , 2011, Cell metabolism.

[51]  H. Randeva,et al.  Fibroblast Growth Factor 21 (FGF21) in Human Cerebrospinal Fluid , 2011, Diabetes.

[52]  Sarah A. Stern,et al.  Astrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation , 2011, Cell.

[53]  Dimitrios Kapogiannis,et al.  Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease , 2011, The Lancet Neurology.

[54]  Eva L. Feldman,et al.  How does diabetes accelerate Alzheimer disease pathology? , 2010, Nature Reviews Neurology.

[55]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[56]  M. Schwartz,et al.  Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats , 2010, Diabetes.

[57]  Pierre J Magistretti,et al.  Role of glutamate in neuron-glia metabolic coupling. , 2009, The American journal of clinical nutrition.

[58]  Winnie S. Liang,et al.  Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons , 2008, Proceedings of the National Academy of Sciences.

[59]  W. Pan,et al.  The fasting polypeptide FGF21 can enter brain from blood , 2007, Peptides.

[60]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[61]  P. Magistretti,et al.  Activity‐dependent regulation of energy metabolism by astrocytes: An update , 2007, Glia.

[62]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[63]  G. Bonvento,et al.  Neuron–astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy , 2006, Journal of neurochemistry.

[64]  P. Magistretti,et al.  Dual-Gene, Dual-Cell Type Therapy against an Excitotoxic Insult by Bolstering Neuroenergetics , 2004, The Journal of Neuroscience.

[65]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[66]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  K. Kosik,et al.  Selective Phosphorylation of Adult Tau Isoforms in Mature Hippocampal Neurons Exposed to Fibrillar Aβ , 1997, Molecular and Cellular Neuroscience.

[68]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[69]  P. Magistretti,et al.  Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Troncoso,et al.  Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.

[71]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[72]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[73]  N. Chattipakorn,et al.  FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[74]  H. Randeva,et al.  Fibroblast Growth Factor 21 ( FGF 21 ) in Human Cerebrospinal Fluid Relationship With Plasma FGF 21 and Body Adiposity , 2011 .

[75]  D. Hines,et al.  Astroglial Metabolic Networks Sustain Hippocampal Synaptic Transmission , 2009 .